WESTFORD, Mass., Jan. 18 /PRNewswire-FirstCall/ -- Cynosure, Inc. , a leading developer and manufacturer of lasers and pulsed light sources, today announced it has received Class II medical device license approval from Health Canada to market and sell its laser-based TriActive(TM) LaserDermology(SM) System for the temporary reduction in the appearance of cellulite, over the counter in Canada.
The TriActive is Cynosure's flagship cellulite product that contains six low-energy diode lasers, mechanical massage and suction and localized cooling.
"We are delighted to further the availability of this proven treatment for the reduction of cellulite's appearance," said Michael R. Davin, Chairman and CEO of Cynosure. "TriActive is the only laser-based system that can be sold over the counter both in the United States and Canada for the temporary reduction of cellulite's appearance, providing us with a significant competitive advantage. The approval by Canada's regulatory body allows us to better serve the Canadian market with an expanded product offering and helps us enhance our share of the rapidly growing emerging cellulite market."
Cellulite is a deposit of fat that causes a dimple or other uneven appearance of the skin on women, typically around the hips, thighs and buttocks. According to published reports, an estimated 80 percent of women have some degree of cellulite. This condition is far more common in women than men due to the way fat, muscle and connective tissues are distributed in women's skin. Cynosure believes that more than 50 million women in the US and Canada between the ages of 20 and 50 suffer from this condition, with many seeking treatment options.
"With the addition of TriActive to our practice, we have seen an increase in patients looking for an effective treatment of cellulite," commented Roger Lam, MD, medical director of Infinity Laser Center in Sherway Gardens, Toronto. "Patients are excited to discover a scientifically proven technique that temporarily reduces unsightly cellulite. This treatment has been instrumental in reducing the appearance of cellulite on the waist, thighs and buttocks. Patients love how easy and relaxing the treatments are."
In addition to temporarily reducing the appearance of cellulite, TriActive treatments have also been shown to temporarily relieve minor pain and muscle spasms.
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse-dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.
For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosurelaser.com/.
Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the markets in which Cynosure's products are sold, and other statements containing the words "believes," "anticipates," "plans," "expects," "will," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's history of operating losses, its reliance on sole source suppliers, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's Registration Statement on Form S-1, as amended, filed with the SEC. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.
First Call Analyst:
FCMN Contact:
© 2006 PR Newswire
